Research programme: bispecific therapeutics - Ambrx/Zhejian Hisun Pharmaceuticals

Drug Profile

Research programme: bispecific therapeutics - Ambrx/Zhejian Hisun Pharmaceuticals

Alternative Names: Bispecifics - Ambrx

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Ambrx
  • Developer Ambrx; Zhejiang Hisun Pharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 29 Apr 2014 Ambrx and Zhejiang Hisun Pharmaceutical agree to co-develop Bispecific therapeutics in China for Cancer
  • 29 Apr 2014 Preclinical development for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top